Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer

26 May 2022

Abstract excerpt

Triple negative breast cancer (TNBC) is an urgent as well as huge medical challenge, which is associated with poor prognosis and responsiveness to chemotherapies. Since epigenetic changes are highly implicated in TNBC tumorigenesis and development, inhibitors of histone deacetylases (HDACIs) could represent a promising therapeutic strategy. Although clinical trials involving single HDACIs showed disappointing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholinesterase and Neurodegenerative Diseases
Share to Histone Deacetylase Inhibitors Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35745586
DOI: 10.3390/ph15060667

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC Inhibitors for the Therapy of Triple Negative Breast CancerPMID 35745586Read ↗

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast CancerSemantic proximity Read ↗

Epi-drugs as triple-negative breast cancer treatmentSemantic proximity Read ↗

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancerSemantic proximity Read ↗

Chimeric HDAC inhibitors: Comprehensive review on the HDAC‐based strategies developed to combat cancerSemantic proximity Read ↗

Recent Advances in the Treatment of Breast CancerSemantic proximity Read ↗

Histone-Deacetylase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsSemantic proximity Read ↗

Epigenetics of Triple-Negative Breast Cancer via Natural CompoundsSemantic proximity Read ↗

Discovery of Novel Class of Histone Deacetylase Inhibitors as Anticancer AgentsSemantic proximity Read ↗

The role of histone deacetylase inhibitors in metastatic breast cancerSemantic proximity Read ↗

Targeted and cytotoxic inhibitors used in the treatment of breast cancerSemantic proximity Read ↗

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.